BR122019020961B8 - uso do ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzóico ou um sal farmaceuticamente aceitável do mesmo - Google Patents

uso do ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzóico ou um sal farmaceuticamente aceitável do mesmo

Info

Publication number
BR122019020961B8
BR122019020961B8 BR122019020961A BR122019020961A BR122019020961B8 BR 122019020961 B8 BR122019020961 B8 BR 122019020961B8 BR 122019020961 A BR122019020961 A BR 122019020961A BR 122019020961 A BR122019020961 A BR 122019020961A BR 122019020961 B8 BR122019020961 B8 BR 122019020961B8
Authority
BR
Brazil
Prior art keywords
benzoic acid
oxadiazol
fluorophenyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BR122019020961A
Other languages
English (en)
Other versions
BR122019020961B1 (pt
Inventor
Miller Langdon
Hirawat Samit
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39102963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122019020961(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of BR122019020961B1 publication Critical patent/BR122019020961B1/pt
Publication of BR122019020961B8 publication Critical patent/BR122019020961B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

a presente invenção se refere a doses específicas e regimes de dosagem para usar um composto de ácido 1,2,4-oxadiazol benzóico no tratamento ou prevenção de doenças associadas com mutações sem sentido. em particular, a invenção se refere a doses específicas e regimes de dosagem para o uso de ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzóico em mamíferos tendo doenças associadas com mutações sem sentido.
BR122019020961A 2006-10-12 2007-10-11 uso do ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzóico ou um sal farmaceuticamente aceitável do mesmo BR122019020961B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85145006P 2006-10-12 2006-10-12
US60/851,450 2006-10-12
BRPI0719276-2A2A BRPI0719276A2 (pt) 2006-10-12 2007-10-11 Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto.
PCT/US2007/021921 WO2008045566A1 (en) 2006-10-12 2007-10-11 Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

Publications (2)

Publication Number Publication Date
BR122019020961B1 BR122019020961B1 (pt) 2021-03-09
BR122019020961B8 true BR122019020961B8 (pt) 2021-07-27

Family

ID=39102963

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019020961A BR122019020961B8 (pt) 2006-10-12 2007-10-11 uso do ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzóico ou um sal farmaceuticamente aceitável do mesmo
BRPI0719276-2A2A BRPI0719276A2 (pt) 2006-10-12 2007-10-11 Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0719276-2A2A BRPI0719276A2 (pt) 2006-10-12 2007-10-11 Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto.

Country Status (24)

Country Link
US (7) US9226919B2 (pt)
EP (2) EP2073805B1 (pt)
JP (4) JP2010506840A (pt)
KR (4) KR20170100072A (pt)
CN (2) CN101553226B (pt)
AU (1) AU2007308067B2 (pt)
BR (2) BR122019020961B8 (pt)
CA (1) CA2675518C (pt)
CL (1) CL2007002923A1 (pt)
DK (1) DK2073805T3 (pt)
ES (1) ES2538359T3 (pt)
HK (2) HK1136214A1 (pt)
HR (1) HRP20150590T1 (pt)
IL (2) IL198147A (pt)
MX (1) MX2009003909A (pt)
NO (1) NO342061B1 (pt)
PE (4) PE20160947A1 (pt)
PL (1) PL2073805T3 (pt)
PT (1) PT2073805E (pt)
RS (1) RS54025B1 (pt)
RU (1) RU2462247C2 (pt)
SI (1) SI2073805T1 (pt)
TW (1) TWI405570B (pt)
WO (1) WO2008045566A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632902B1 (en) 2003-04-11 2021-07-14 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
MX2008012515A (es) * 2006-03-30 2008-11-19 Ptc Therapeutics Inc Metodos para la produccion de proteina funcional a partir de adn que tiene una mutacion sin sentido y el tratamiento de trastornos asociados con la misma.
CN101553226B (zh) * 2006-10-12 2015-05-13 Ptc医疗公司 给用口服活性1,2,4-噁二唑进行无义突变抑制治疗的方法
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
KR102497273B1 (ko) * 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
EP3825305A1 (en) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Process for preparing lenvatinib
PT3263106T (pt) 2015-02-25 2024-01-12 Eisai R&D Man Co Ltd Método para suprimir o amargor do derivado de quinolina
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
BR112018008838A8 (pt) 2015-10-30 2019-02-26 Ptc Therapeutics Inc método para tratar, prevenir, melhorar ou administrar uma doença epiléptica
BR112020007740A2 (pt) 2017-10-19 2020-10-13 Cipla USA, Inc. síntese de análogos de aminoglicosídeos antibacterianos
EP3713934B1 (en) 2017-11-23 2022-04-13 Universita' degli Studi di Palermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
WO2022177269A1 (ko) * 2021-02-16 2022-08-25 라이보텍(주) 넌센스-매개 mrna 분해를 억제하기 위한 화합물
KR102378381B1 (ko) * 2021-08-23 2022-03-24 라이보텍(주) 넌센스-매개 mRNA 분해를 억제하기 위한 화합물
EP4337267A1 (en) * 2021-05-11 2024-03-20 RegenxBio Inc. Treatment of duchenne muscular dystrophy and combinations thereof
KR102665711B1 (ko) * 2021-12-21 2024-05-14 재단법인 아산사회복지재단 Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2449544A1 (en) 2001-06-08 2002-12-19 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
MXPA05001592A (es) 2002-08-09 2005-05-05 Astrazeneca Ab Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP3632902B1 (en) * 2003-04-11 2021-07-14 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
KR20060123493A (ko) * 2003-12-23 2006-12-01 알자 코포레이션 제어된 전달을 위한 약물 조성물의 용해도를 증가시키는방법 및 제형
PT2402002T (pt) * 2005-04-08 2018-10-08 Ptc Therapeutics Inc Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
US20070010553A1 (en) 2005-07-01 2007-01-11 Astrazeneca Ab New use
DK2059513T3 (da) 2006-09-08 2013-05-06 Ptc Therapeutics Inc Fremgangsmåde til fremstillingen af 1,2,4-oxadiazolbenzoesyrer
AR062963A1 (es) 2006-09-25 2008-12-17 Ptc Therapeutics Inc Forma cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico
CN101553226B (zh) 2006-10-12 2015-05-13 Ptc医疗公司 给用口服活性1,2,4-噁二唑进行无义突变抑制治疗的方法

Also Published As

Publication number Publication date
CL2007002923A1 (es) 2008-06-06
US20080114039A1 (en) 2008-05-15
US9737513B2 (en) 2017-08-22
ES2538359T3 (es) 2015-06-19
EP2460520A1 (en) 2012-06-06
IL198147A (en) 2016-02-29
AU2007308067B2 (en) 2013-05-30
TWI405570B (zh) 2013-08-21
KR20160128468A (ko) 2016-11-07
PT2073805E (pt) 2015-07-13
BR122019020961B1 (pt) 2021-03-09
JP2014058533A (ja) 2014-04-03
JP2010506840A (ja) 2010-03-04
IL236519A (en) 2017-03-30
US9226919B2 (en) 2016-01-05
BRPI0719276A2 (pt) 2014-04-29
NO20091826L (no) 2009-07-08
US20160101087A1 (en) 2016-04-14
WO2008045566B1 (en) 2008-06-19
CN103211766B (zh) 2015-03-11
IL198147A0 (en) 2009-12-24
NO342061B1 (no) 2018-03-19
US10172836B2 (en) 2019-01-08
US20170049752A1 (en) 2017-02-23
KR20170100072A (ko) 2017-09-01
PE20120670A1 (es) 2012-06-01
TW200820968A (en) 2008-05-16
US20170304275A1 (en) 2017-10-26
PL2073805T3 (pl) 2015-08-31
HRP20150590T1 (hr) 2015-07-03
US9877952B2 (en) 2018-01-30
US9522137B2 (en) 2016-12-20
RU2462247C2 (ru) 2012-09-27
PE20160947A1 (es) 2016-09-26
JP6129713B2 (ja) 2017-05-17
EP2460520B1 (en) 2015-09-30
KR101758341B1 (ko) 2017-07-14
KR20090074231A (ko) 2009-07-06
WO2008045566A1 (en) 2008-04-17
US10849885B2 (en) 2020-12-01
PE20212245A1 (es) 2021-11-24
HK1170690A1 (zh) 2013-03-08
AU2007308067A1 (en) 2008-04-17
CN103211766A (zh) 2013-07-24
US20180140583A1 (en) 2018-05-24
DK2073805T3 (da) 2015-06-15
US20190099405A1 (en) 2019-04-04
MX2009003909A (es) 2009-05-25
CA2675518A1 (en) 2008-04-17
CA2675518C (en) 2017-11-14
RS54025B1 (en) 2015-10-30
SI2073805T1 (sl) 2015-10-30
KR20150064244A (ko) 2015-06-10
JP6333227B2 (ja) 2018-05-30
US20210038572A1 (en) 2021-02-11
PE20080982A1 (es) 2008-07-19
JP2017081946A (ja) 2017-05-18
EP2073805B1 (en) 2015-03-04
CN101553226A (zh) 2009-10-07
RU2009117590A (ru) 2010-11-20
IL236519A0 (en) 2015-02-26
JP2016029078A (ja) 2016-03-03
CN101553226B (zh) 2015-05-13
HK1136214A1 (en) 2010-06-25
EP2073805A1 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
BR122019020961B8 (pt) uso do ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzóico ou um sal farmaceuticamente aceitável do mesmo
AR118922A2 (es) Procesos para la preparación de ácidos de 1,2,4-oxadiazol benzoico
NO20075682L (no) Sammensetninger omfattende et oralt aktivt 1,2,4-oksadiazol for nonsense mutasjonsundertrykkelsesterapi
TW200637558A (en) Solid, modified-release pharmaceutical dosage forms which can be administered orally
CU23808B7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
JP2016512558A5 (pt)
PE20142292A1 (es) Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus metodos y usos
NZ591169A (en) Combination therapy for tuberculosis
SMP200700047B (it) Forme di dosaggio di risedronato
NZ590268A (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
JP2016512507A5 (pt)
AR061332A1 (es) Compuesto de oxadiazol como inhibidor de dgat1(diacilglicerol aciltransferasa)
HK1130252A1 (en) Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders
BR0308806A (pt) Uso de oxazolidinonas para tratar infecções do tipo pé diabético
NZ594561A (en) A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
MA35636B1 (fr) Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide
TW200616625A (en) Agent for prophylaxis or treatment of metabolic syndrome
NO20092695L (no) Profylaktisk eller terapeutisk middel for alopeki
MA30510B1 (fr) Nouveau cristal d'acide 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]propionique
AR054059A1 (es) Compuesto de 1-3 tiazol 4-(5h) ona composiciones que lo comprenden y su uso para preparar un medicamento
CY1116360T1 (el) Μεθοδοι για δοσολογηση μιας εκ του στοματος χορηγουμενης δραστικης 1,2,4-οξαδιαζολης για θεραπεια καταστολης μη-νοηματικων μεταλλαξεων
CY1113938T1 (el) Διαδικασιες για την παρασκευη 1,2,4-οξαδιαζολο βενζοϊκων οξεων
WO2009024820A3 (en) Therapeutic treatment 014
NZ737837A (en) Soft chewable pharmaceutical products

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16D Grant of patent or certificate of addition of invention cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 16.1 NA RPI NO 2611 DE 19/01/2021 POR TER SIDO INDEVIDA.

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UM PARECER DE DEFERIMENTO NOTIFICADO NA RPI NO 2608 DE 29/12/2020, TENDO SIDO CONSTATADO QUE ESTA NOTIFICACAO FOI EFETUADA COM INCORRECOES. A PETICAO RJ NO 870190099723 DE 04/10/2019 POSSUI TAMBEM DESENHOS, E ESTES FORAM IGNORADOS NO PARECER ACIMA MENCIONADO. PORTANTO, RETIFICA-SE A REFERIDA PUBLICACAO.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/10/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO